• Anti-InflammatoryCompleted with Results

  KB001-A in people with CF and Pseudomonas aeruginosa , protocol number KaloBios KB001-05

  This study evaluated the safety and effectiveness of the drug KB001-A compared with placebo. This study was for people who have chronic Pseudomonas aeruginosa (Pa) airway infection.

  • Age:

    12 Years to 50 Years

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40 to 100%

  • Number of Visits:

    10

  • Length of Participation:

    20 weeks

• Anti-InflammatoryCompleted with Results

  Safety Study of KB001 in People with CF and Pseudomonas aeruginosa , protocol number Kalobios KB001-03

  This study looked the safety and effectiveness of a single-dose of an investigational drug (KB001) on inflammation and on levels of Pseudomonas aeruginosa in the lungs of people with CF.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40% or greater

  • Number of Visits:

    6

  • Length of Participation:

    10 weeks

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.